

VISCHER ADVISED AZAFAROS IN ITS EXECUTIVE EXPANSION AND OPERATIONS

Posted on 15 July 2020



Category: [Deal & transactions](#)

Tags: [Christian Wyss](#), [Ex-Featured](#), [Francesca Pesenti](#), [Gian Geel](#), [Timothy Woodtli](#), [Vischer](#)



Azafaros, headquartered in Leiden, The Netherlands, has recently incorporated a Swiss subsidiary in the pharma hub of Basel to strengthen its research and development operations. In addition, three experienced industry executives have joined the company: Kyle Landskroner as Head of Preclinical Drug Development, Ruben Giorgino as Head of Clinical Research and Development and Louise Kooij as Head of Finance and Operations. The new members are together with Chief Executive Officer, Olivier Morand, form the Azafaros executive management team. Azafaros is supported by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures, BioMedPartners and Schroder Adveq.

The advisor

VISCHER [advised on all Swiss legal issues](#) related to the transaction. The team included partner Christian Wyss (Life Sciences - pictured), associate Timothy Woodtli (Corporate/M&A), associate Francesca Pesenti (Corporate/M&A), and associate Gian Geel (Employment).